DHR Health Encourages Early Detection with $99 Lung Cancer Screening Special Thru Dec. 31st

Translate to Spanish or other 102 languages!

In recognition of Lung Cancer Awareness Month, observed every November, DHR Health is offering a $99 low-dose CT lung cancer screening now through December 31, 2025, to promote early detection and save lives. Image courtesy of DHR Health
In recognition of Lung Cancer Awareness Month, observed every November, DHR Health is offering a $99 low-dose CT lung cancer screening now through December 31, 2025, to promote early detection and save lives. Image courtesy of DHR Health
- Advertisement -

EDINBURG, Texas –  Lung cancer remains the leading cause of cancer death in the United States, accounting for about one in five cancer deaths nationwide. According to the American Cancer Society, an estimated 226,650 new cases of lung cancer will be diagnosed in 2025, and 124,730 people are expected to die from the disease. Each year, lung cancer claims more lives than colon, breast, and prostate cancers combined.

Despite these concerning statistics, there is hope through earlier detection. The American Lung Association reports that annual screening with low-dose computed tomography (LDCT) scans can reduce lung cancer deaths by up to 20 percent by identifying cancer at an earlier, more treatable stage.

In recognition of Lung Cancer Awareness Month, observed every November, DHR Health is offering a $99 low-dose CT lung cancer screening now through December 31, 2025, to promote early detection and save lives. The special includes both the screening and radiologist interpretation and requires a referral from a health care provider. Eligible individuals include current or former smokers between the ages of 50 and 80, for most insurances. Individuals outside this age group who are current or former smokers are encouraged to speak with a health care provider about their options.

- Advertisement -

To support early detection and timely treatment, DHR Health combines advanced technology and expert care. If a low-dose CT scan identifies a suspicious nodule, the Eon artificial intelligence system helps flag potential findings for the care team. When further evaluation is needed, the Ion robotic-assisted bronchoscopy system enables pulmonary specialists to biopsy lung nodules with precision—providing patients with fast, accurate results and timely care.

These efforts have contributed to DHR Health’s dual designations as a Center of Excellence in Lung Cancer Screening and a Center of Excellence in Lung Cancer Care, highlighting the hospital’s commitment to innovation, quality, and patient-centered outcomes.

“Lung cancer doesn’t always cause symptoms early on, which is why screenings are so critical,” said Dr. Federico Vallejo, DHR Health pulmonologist and robotic-assisted bronchoscopist. “When we catch it early, we have a real opportunity to save lives. By using the latest technology and encouraging people to get screened, we can catch lung cancer earlier—when it’s most treatable.”

DHR Health encourages those at risk to take advantage of this limited-time promotion and prioritize their lung health through early screening. For more information, assistance with getting a low-dose CT referral, or to schedule your appointment, please call (956) 362-LUNG (5864) to speak with the DHR Health Lung Navigator.

Courtesy of DHR Health
- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Study: Supplement Plus Chemo Boosts Pancreatic Cancer Survival

L-glutamine, an amino acid that occurs naturally in the body and plays an important role in digestion, has been studied as a potential way to ease side effects in other cancers.

How Artificial Intelligence Is Improving Prostate Cancer Diagnostics

Mega Doctor News CLEVELAND CLINIC - September is Prostate Cancer Awareness Month.  Prostate cancer is...

FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder

The U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells.

FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

Lisraya is the first FDA-approved oral treatment option for patients with dermatomyositis, addressing the high unmet need for this rare disease.
- Advertisement -